The DOI matches its Crossref record; 30 of the 32 references it cites were found in a registry or an index.
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Open accessAbstract
Background Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract cancer is chemotherapy with gemcitabine and cisplatin. Because most biliary tract cancers have an immune-suppressed microenvironment, immune checkpoint inhibitor monotherapy is associated with a low objective response rate. We aimed to assess whether adding the immune checkpoint inhibitor pembrolizumab to gemcitabine and cisplatin would improve outcomes compared with gemcitabine and cisplatin alone in patients with advanced biliary tract cancer.Methods KEYNOTE-966 was a randomised, double-blind, placebo-controlled, phase 3 trial done at 175 medical centres globally. Eligible participants were aged 18 years or older; had previously untreated, unresectable, locally advanced or metastatic biliary tract cancer; had disease measurable per Response Evaluation Criteria in Solid Tumours version 1.1; and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible participants were randomly assigned (1:1) to pembrolizumab 200 mg or placebo, both administered intravenously every 3 weeks (maximum 35 cycles), in combination with gemcitabine (1000 mg/m 2 intravenously on days 1 and 8 every 3 weeks; no maximum duration) and cisplatin (25 mg/m 2 intravenously on days 1 and 8 every 3 weeks; maximum 8 cycles). Randomisation was done using a central interactive voice-response system and stratified by geographical region, disease stage, and site of origin in block sizes of four. The primary endpoint of overall survival was evaluated in the intention-to-treat population. The secondary endpoint of safety was evaluated in the as-treated population. This study is registered at ClinicalTrials.gov, NCT04003636.Findings Between Oct 4, 2019, and June 8, 2021, 1564 patients were screened for eligibility, 1069 of whom were randomly assigned to pembrolizumab plus gemcitabine and cisplatin (pembrolizumab group; n=533) or placebo plus gemcitabine and cisplatin (placebo group; n=536). Median study follow-up at final analysis was 25·6 months (IQR 21·7-30·4). Median overall survival was 12·7 months (95% CI 11·5-13·6) in the pembrolizumab group versus 10·9 months (9·9-11·6) in the placebo group (hazard ratio 0·83 [95% CI 0·72-0·95]; one-sided p=0·0034 [significance threshold, p=0·0200]). In the as-treated population, the maximum adverse event grade was 3 to 4 in 420 (79%) of 529 participants in the pembrolizumab group and 400 (75%) of 534 in the placebo group; 369 (70%) participants in the pembrolizumab group and 367 (69%) in the placebo group had treatment-related adverse events with a maximum grade of 3 to 4. 31 (6%) participants in the pembrolizumab group and 49 (9%) in the placebo group died due to adverse events, including eight (2%) in the pembrolizumab group and three (1%) in the placebo group who died due to treatment-related adverse events.Interpretation Based on a statistically significant, clinically meaningful improvement in overall survival compared with gemcitabine and cisplatin without any new safety signals, pembrolizumab plus gemcitabine and cisplatin could be a new treatment option for patients with previously untreated metastatic or unresectable biliary tract cancer.Funding Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, results from phase III trials in advanced BTC patients showed that the addition of pembrolizumab to cisplatin/gemcitabine revealed an improvement in OS compared to cisplatin/gemcitabine alone without any new safety signals (mOS: 12·7 vs. 10·9 months; one-sided P = 0.0034 [significance threshold P = 0.02]) [110].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [110]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Self-citationTerrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Self-citationMarabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Self-citationDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Oh, D.-Y., Ruth He, A., Qin, S., Chen, L.-T., Okusaka, T., Vogel, A., Kim, J. W., Suksombooncharoen, T., Ah Lee, M., Kitano, M., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200015 · Cited by 1,217
Self-citationValle, J. W., Kelley, R. K., Nervi, B., Oh, D.-Y., & Zhu, A. X. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00153-7 · Cited by 1,043
Self-citationWhole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma
Jusakul, A., Cutcutache, I., Yong, C. H., Lim, J. Q., Huang, M. N., Padmanabhan, N., Nellore, V., Kongpetch, S., Ng, A. W. T., Ng, L. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0368 · Cited by 969
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Lamarca, A., Palmer, D. H., Wasan, H. S., Ross, P. J., Ma, Y. T., Arora, A., Falk, S., Gillmore, R., Wadsley, J., Patel, K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00027-9 · Cited by 769
Self-citationGarassino, M. C., Gadgeel, S., Speranza, G., Felip, E., Esteban, E., Dómine, M., Hochmair, M. J., Powell, S. F., Bischoff, H. G., Peled, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01989 · Cited by 733
Cited by
Oh, D.-Y., He, A. R., Bouattour, M., Okusaka, T., Qin, S., Chen, L.-T., Kitano, M., Lee, C.-K., Kim, J. W., Chen, M.-H., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00095-5 · Cited by 308
Self-citationHarding, J. J., Fan, J., Oh, D.-Y., Choi, H. J., Kim, J. W., Chang, H.-M., Bao, L., Sun, H.-C., Macarulla, T., Xie, F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00242-5 · Cited by 291
Self-citationMetabolic reprogramming in the tumor microenvironment of liver cancer
Lin, J., Rao, D., Zhang, M., & Gao, Q. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01527-8 · Cited by 251
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Ilyas, S. I., Affo, S., Goyal, L., Lamarca, A., Sapisochin, G., Yang, J. D., & Gores, G. J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00770-1 · Cited by 217
Yang, H., Cheng, J., Zhuang, H., Xu, H., Wang, Y., Zhang, T., Yang, Y., Qian, H.-G., Lu, Y., Han, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.004 · Cited by 184
Self-citation
Metadata
- Authors
- Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., Verslype, C., Bouattour, M., Park, J. O., Barajas, O., Pelzer, U., Valle, J. W., Yu, L., Malhotra, U., Siegel, A. B., Edeline, J., Vogel, A., Akce, M., Ales Diaz, I., Alves, G., Anand, S., Arslan, C., Asselah, J., Assenat, E., Aubin, F., Bai, L.-Y., Bai, Y., Barajas, O., Bates, S., Begbie, S., Ben-Aharon, I., Beri, N., Berres, M.-L., Blanc, J.-F., Borbath, I., Bordonaro, R., Bouattour, M., Brandi, G., Burgoyne, A., Butthongkomvong, K., Camandaroba, M., Cao, K., Carballido, M., Chan, S. L., Chen, J.-S., Chen, M.-H., Chen, X., Cheng, A., Chiu, T.-J., Choi, H. J., Chon, H. J., Collignon, J., Cubillo Gracian, A., Davis, S., de Carvalho, R. S., de Groot, D. J. A., Demols, A., De Vos, J., Diab, M., Easaw, J., Eatock, M., Edeline, J., Elias, R., Eskens, F., Falcone, A., Fernandez, P., Finn, R., Franke, F., Furukawa, M., Furuse, J., Gbolahan, O., Geboes, K., Geneser, K.-L., Geng, Z., Geva, R., Gillmore, R., Goetze, T., Gou, H., Grasselli, J., Gu, S., Gumus, M., Haj Mohammad, N., Hao, C., Harputluoglu, H., Hatoum, H., Heinemann, V., Ho, W. K., Hsu, C., Hubert, A., Hwang, J., Inanc, M., Iseas, S., Jeyasingam, V., Jimenez Fonseca, P., Joubert, W., Juengsamarn, J., Kaen, D., Kanai, M., Kasper-Virchow, S., Kazemi, G., Kelleher, F., Kelley, R., Kim, J. W., Kim, J. G., Kinupe Abrahao, A. B., Klumpen, H., Kochenderfer, M., Kose, F., Lam, H. C., Lee, C.-K., Lee, H. W., Lee, M., Lee, M. A., Lee, W. M. S., Le Sourd, S., Li, D., Li, W., Liang, H., Liang, T., Lim, C. S., Lingerfelt, B., Lopez, C., Low, J., Macarulla Mercade, T., Malka, D., Mao, Y., Masi, G., McCune, S., McDermott, R., McWhirter, E., Mendez, G., Milella, M., Mizuno, N., Mizutani, T., Moniz, C., Morales, L., Munoz Martin, A. J., Nervi, B., Ngamphaiboon, N., Oh, S. C., Oksuzoglu, B., Outlaw, D., Ozaka, M., Ozguroglu, M., Ozyilkan, O., Painemal, C., Pan, Y., Park, J. O., Pelzer, U., Peng, C., Petorin, C., Pezet, D., Power, D., Qin, S., Ren, Z., Roohullah, A., Ryu, H., Salman, P., Sasaki, M., Sasidharan, R., Satoh, T., Schulze, K., Scott-Brown, M., Segovia, R., Seufferlein, T., Siena, S., Sinapi, I., Smolenschi, C., Song, T., Sookprasert, A., Soparattanapaisarn, N., Starling, N., Stein, S., Stemmer, S., Su, H., Sugimoto, R., Suksombooncharoen, T., Tam, V., Tan, A. L., Tan, C. K., Tanasanvimon, S., Tonini, G., Tortora, G., Tsuji, A., Ueno, M., Uribe, R., Venerito, M., Verdaguer Mata, H., Verslype, C., Victorino, A. P., Vogel, A., Wade, J., Waldschmidt, D. T., Wang, L., Wan Isahk, W. Z., Wasan, H., Weschenfelder, R., Wong, C. Y., Wong, Y. F., Yalcin, S., Yanez Weber, P., Yang, X., Yasui, H., Yau, T., Yazici, O., Yen, C.-J., Ying, J., Yoo, C., Yu, W., & Zhao, H.
- Affiliations
- University of California, San Francisco (US)
- University of California, Los Angeles (US)
- Chinese University of Hong Kong (HK)
- University of Manchester (GB)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Inserm (FR)
- Samsung Medical Center (KR)
- University of Hong Kong (HK)
- Amsterdam University Medical Centers (NL)
- ORCID
- Kelley, Robin Kate
- Finn, Richard S
- Chan, Stephen L
- Valle, Juan W
- Yu, Li
- Malhotra, Usha
- Siegel, Abby B
- Akce, Mehmet
- Asselah, Jamil
- Bai, Li-Yuan
- Bai, Yuxian
- Bates, Susan
- Begbie, Stephen
- Beri, Nina
- Berres, Marie-Luise
- Borbath, Ivan
- Brandi, Giovanni
- Burgoyne, Adam
- Butthongkomvong, Kritiya
- Camandaroba, Marcos
- Chiu, Tai-Jan
- Choi, Hye Jin
- Chon, Hong Jae
- Demols, Anne
- Diab, Maria
- Elias, Rawad
- Falcone, Alfredo
- Franke, Fabio
- Furukawa, Masayuki
- Gbolahan, Olumide
- Geboes, Karen
- Geva, Ravit
- Gillmore, Roopinder
- Goetze, Thorsten
- Gou, Hongfeng
- Grasselli, Julieta
- Gu, Shanzhi
- Hao, Chunyi
- Hatoum, Hassan
- Heinemann, Volker
- Hsu, Chiun
- Iseas, Soledad
- Juengsamarn, Jitlada
- Kanai, Masashi
- Kazemi, Ghazaleh
- Kelleher, Fergal
- Kim, Jin Won
- Kim, Jong Gwang
- Lee, Choong-kun
- Lee, Hyun Woo
- Li, Dongliang
- Liang, Tingbo
- Lim, Chun Sen
- Lopez, Charles
- Malka, David
- Mao, Yimin
- Masi, Gianluca
- McCune, Steven
- McDermott, Ray
- McWhirter, Elaine
- Mendez, Guillermo
- Mizuno, Nobumasa
- Mizutani, Tomonori
- Moniz, Camila
- Morales, Luisa
- Nervi, Bruno
- Ngamphaiboon, Nuttapong
- Oh, Sang Cheul
- Outlaw, Darryl
- Pan, Yueyin
- Peng, Chuang
- Pezet, Denis
- Power, Derek
- Qin, Shukui
- Roohullah, Aflah
- Ryu, Hyewon
- Salman, Pamela
- Sasaki, Mitsuhito
- Satoh, Taroh
- Schulze, Kornelius
- Scott-Brown, Martin
- Seufferlein, Thomas
- Siena, Salvatore
- Smolenschi, Cristina
- Song, Tianqiang
- Sookprasert, Aumkhae
- Starling, Naureen
- Stein, Stacey
- Stemmer, Salomon
- Su, Haichuan
- Sugimoto, Rie
- Suksombooncharoen, Thatthan
- Tam, Vincent
- Tan, Ai Lian
- Tanasanvimon, Suebpong
- Tonini, Giuseppe
- Tortora, Giampaolo
- Venerito, Marino
- Victorino, Ana Paula
- Wang, Lu
- Weschenfelder, Rui
- Yasui, Hisateru
- Yen, Chia-Jui
- Ying, Jieer
- Zhao, Haitao
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-06
- Volume
- 401
- Issue
- 10391
- Pages
- 1853-1865
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4365998338
- Cited by
- 1,169
- References
- 32
- Citations by year
- 2026: 358 · 2025: 418 · 2024: 302 · 2023: 89
- FWCI
- 311.55
- Type
- journal article
- Language
- en
- Update notices
- Open access
- Licence
- other-oa
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- HAL (submittedVersion, cc-by-nc)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion, cc-by-nc-nd)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Merck Sharp and Dohme
- Topics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
- Keywords
- pembrolizumab, gemcitabine, cisplatin, biliary tract cancer, immune checkpoint inhibitors, combination chemotherapy, overall survival, immune-related adverse events, anti-PD-1 therapy, metastatic cholangiocarcinoma, gallbladder cancer, cholangiocarcinoma, safety and tolerability
- MeSH terms
- Immune Checkpoint Inhibitors, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms, Cisplatin, Double-Blind Method, Humans, Tumor Microenvironment, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)00727-4
- The paper
- Kelley, R. K., Ueno, M., Yoo, C., Finn, R. S., Furuse, J., Ren, Z., Yau, T., Klümpen, H.-J., Chan, S. L., Ozaka, M., Verslype, C., Bouattour, M., Park, J. O., Barajas, O., Pelzer, U., Valle, J. W., Yu, L., Malhotra, U., Siegel, A. B., . . . Zhao, H. (2023). Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)00727-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.